Samsung Biologics has agreed to acquire Switzerland-based PolyPeptide Group in an all-cash transaction valued at 1.46 billion Swiss francs, or approximately $1.8 billion (2.7 trillion won).
The deal targets PolyPeptide’s specialized capabilities in peptide-based active pharmaceutical ingredients, a segment seeing rapid growth as biopharma companies shift toward complex small-molecule therapies.
The acquisition represents a significant strategic move for Samsung Biologics, which has been aggressively expanding its global footprint and service offerings beyond traditional biologics.
By integrating PolyPeptide’s technology and manufacturing infrastructure, the South Korean contract development and manufacturing organization (CDMO) aims to capture a larger share of the lucrative peptide market, which is projected to grow substantially over the next decade.
PolyPeptide Group, based in Switzerland, brings established expertise in peptide synthesis and purification.
The all-cash structure suggests Samsung Biologics is confident in the immediate strategic value of the assets, avoiding the dilution that would come with a stock-based deal.